ECCO | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
ECCO

An SI Board Since November 2005

Posts	SubjectMarks	Bans
54	5	0

Emcee: John McCarthy	Type: Unmoderated

Introduction Compact

If you would, in addition to where you would ordinarily
post ECCO abstracts:would you ALSO post them here?

The point of this thread is to have [all] the abstracts
in one place.

If there is ALREADY a board to do this - then just
ignore this borad.

Final RULES - the purpose of this thread is twofold:

(a) Post the ECCO abstracts

(b) Commentary (yeh and nay ) about the findings is WELCOME but please but lets leave the "Alice this is gonna go to the moon" stuff to the respective stock board.

regards,
John

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
54	Rick - thanks ... but the truth is its YOU GUYS AND GALS .... (theres around	John McCarthy	-	11/3/2005
53	opportunity that you handed to us on silver platter. thanks.	scaram(o)uche	-	11/3/2005
52	Panitumumab - Abstract 653: First line therapy of Panitumumab, a fully human an	John McCarthy	-	11/3/2005
51	Panitumumab - Abstract 1123: Panitumumab, a fully human antibody, combined wi	John McCarthy	-	11/3/2005
50	New treatment options for patients with prostate cancer Wed Nov 2 06:33:05 200	John McCarthy	-	11/2/2005
49	New ECCO studies highlight promising potential of cancer immunotherapy Wed Nov	John McCarthy	-	11/2/2005
48	Sutent - Abstract 40: Systemic therapy and novel targeted therapies in renal ca	John McCarthy	-	11/2/2005
47	Sorafenib - Abstract 943: Phase II study of Sorafenib (BAY 43-9006) in combinat	John McCarthy	-	11/2/2005
46	Sorafenib - Abstract 864: Phase II study of BAY 43-9006 (sorafenib) in patients	John McCarthy	-	11/2/2005
45	Sorafenib - Abstract 863: A phase II study of BAY 43-9006 (sorafenib) in patien	John McCarthy	-	11/2/2005
44	Sorafenib - Abstract 795: Phase II trial of sorafenib (BAY 43-9006) in combinat	John McCarthy	-	11/2/2005
43	Sorafenib - Abstract 794: Randomized Phase III trial of the multi-kinase inhibi	John McCarthy	-	11/2/2005
42	Sorafenib - Abstract 276: A Phase II multicentre uncontrolled trial of sorafeni	John McCarthy	-	11/2/2005
41	Sorafenib - Abstract 1210: Phase I trial of sorafenib (BAY 43-9006) combined wi	John McCarthy	-	11/2/2005
40	Sorafenib - Abstract 1029: A Phase II study of Sorafenib (BAY 43-9006) in patie	John McCarthy	-	11/2/2005
39	gefitinib (IRESSA) - Abstract 959: Evaluation of gefinitib in combination with	John McCarthy	-	11/2/2005
38	gefitinib (IRESSA) - Abstract 876: Combined treatment with Bicalutamide and ZD-	John McCarthy	-	11/2/2005
37	gefitinib (IRESSA) - Abstract 700: Phase I/II trial of capecitabine and gefitin	John McCarthy	-	11/2/2005
36	gefitinib (IRESSA) - Abstract 1462: A multicenter Phase II trial of gefitinib 5	John McCarthy	-	11/2/2005
35	gefitinib (IRESSA) - Abstract 1178: Nuclear Factor-kappa B activation by TNF-al	John McCarthy	-	11/2/2005
34	gefitinib (IRESSA) versus ZD6474 - Abstract 1124: Results of a randomized, doub	John McCarthy	-	11/2/2005
33	gefitinib (IRESSA) - Abstract 1087: A phase III trial of gefitinib (IRESSA) and	John McCarthy	-	11/2/2005
32	Erbitux - Abstract 702: Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic	John McCarthy	-	11/2/2005
31	Erbitux - Abstract 699: Cutaneous and non-cutaneous toxicity induced by biologi	John McCarthy	-	11/2/2005
30	Erbitux - Abstract 664: Cetuximab in combination with irinotecan/5-fluorouracil	John McCarthy	-	11/2/2005

Go to reply# or date (mm/dd/yy):